[ Ocugen raises $7.5M in Series B ]
Ocugen has raised $7.5 million in Series B funding.
Founded in 2013, Ocugen is a biotechnology company focusing on developing novel biologicals targeting unmet medical needs in treating complex eye diseases.
The company will use the new financing for the advancement of potential sight-saving ophthalmology products into clinical trials.
|Founder / CEO||Shankar Musunuri Musunuri|
|Investors||Abdi Ibrahim Pharmaceuticals|
|Previous Investors||EB5 Life Sciences|